$73.87 0.56 (+0.76%)
2/10/2012 4:02 PM

Edwards Lifesciences Corp (NYSE:EW)

CAPS Rating: 3 out of 5

A global provider of products and technologies designed to treat advanced cardiovascular disease. The Company focuses on specific cardiovascular opportunities including heart valve disease, peripheral vascular disease and critical care technologies.

Results 1 - 14 of 14

Recs

0
Member Avatar jmclr (99.61) Submitted: 2/7/2012 11:24:33 PM : Outperform Start Price: $72.72 EW Score: +1.33

73.21

Recs

0
Member Avatar racoveanul (83.63) Submitted: 11/12/2011 8:14:06 AM : Underperform Start Price: $70.40 EW Score: +1.55

I believe Edwards Lifescien will bring in 92.81 points considering a 15% S&P performance. My target is $ 16.88.

Recs

0
Member Avatar tbonci (66.48) Submitted: 10/20/2011 11:05:33 AM : Outperform Start Price: $71.68 EW Score: -8.41

Good returns, great products, eyes on worldwide delivery.

Recs

0
Member Avatar gorjo (< 20) Submitted: 5/10/2011 3:11:08 AM : Outperform Start Price: $88.20 EW Score: -15.65

Innovative new technology. Industry leader.

Recs

0
Member Avatar lacostakid (71.46) Submitted: 12/31/2010 2:07:08 PM : Outperform Start Price: $81.53 EW Score: -15.43

good sales and earnings growth

Recs

0
Member Avatar lmlawl (< 20) Submitted: 12/27/2010 4:29:08 PM : Outperform Start Price: $79.98 EW Score: -13.22

new product to get fda approval

Recs

0
Member Avatar blocksofstock (< 20) Submitted: 10/18/2010 2:29:57 PM : Outperform Start Price: $67.00 EW Score: -3.35

Pipeline pdts. + candidate to be bought

Recs

0
Member Avatar WilliamCrook2007 (< 20) Submitted: 11/20/2008 2:47:03 PM : Outperform Start Price: $23.23 EW Score: +143.48

ibd

Recs

0
Member Avatar robo2011 (98.85) Submitted: 7/20/2008 11:32:25 PM : Underperform Start Price: $33.13 EW Score: -113.36

Overvalued and at the top of a 52 week high, this stock is ripe and ready for a fall.

Recs

0
Member Avatar jetlith (23.60) Submitted: 7/3/2008 4:06:35 PM : Underperform Start Price: $30.79 EW Score: -130.59

gone up wayyyyyy too high, especially in this bear market.. and YoY eps has been dropping big. I expect a correction back down to the 40's.

Recs

0
Member Avatar ScreenerStizBear (< 20) Submitted: 6/26/2008 2:29:59 PM : Underperform Start Price: $31.15 EW Score: -129.62

I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!

Recs

0
Member Avatar joelima (< 20) Submitted: 4/11/2008 4:08:21 PM : Outperform Start Price: $23.12 EW Score: +214.41

Great pipeline

Recs

0
Member Avatar ll0o0ll (99.09) Submitted: 5/21/2007 10:49:14 AM : Outperform Start Price: $24.84 EW Score: +204.35

Terrific company ttat pursue a technology to allow cardio vault placement without major surgery.

Recs

3
Member Avatar NetscribeMedDevs (89.14) Submitted: 2/26/2007 7:51:36 AM : Outperform Start Price: $25.92 EW Score: +187.14

Cardiovascular diseases is the number one cause of death world wide and is among the top three diseases in terms of health care spending in nearly every country. In the U.S. alone it is slated to affect 7 million people annually and the number is more or less same in countries around the world. Edward life systems operate in this area providing products and technology that caters to advanced cardiovascular diseases.

The company operates through five product lines namely Heart valve therapy, Critical care, Cardiac Surgery system, Vascular and other distribution products. The company is the market leader in the $1.1 billion heart valve market, which contributes about 48% of total revenue. Critical care chips in with 32% and the rest three segments contribute the rest almost equally. The company also has a spread out geographical presence with revenues coming from North America, Europe, Japan and Other International Markets in the proportion 50%, 22%, 18% and 10% respectively.

The heart valve market is undergoing a shift from mechanical valves to tissue-based valves, which strengthens Edward’s position, as the company is traditionally strong in the segment. The market for such valves is expect to grow at 7% annual, but Edward’s unique position puts it in a 9% per annum growth track as it has a first mover advantage. Also Stent products are going to revolutionalise the manner, in which cardiovascular diseases are treated, and the company with new products introduced in this segment is trying to make the most of the opportunity. The future thus looks promising for the company, as they have caught the tide at the right time and at the right place. Now all that is left is to sail the course.

Results 1 - 14 of 14

Featured Broker Partners


Advertisement